Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Feature|Videos|May 28, 2024
A Different CDMO Experience: Q&A With Scorpius’ President & COO Joe Payne
Author(s)Scorpius BioManufacturing
Joe Payne, Scorpius BioManufacturing, comments on the unique needs of today's biopharmaceutical companies looking to develop and manufacture small-volume, early-stage large molecules.
Watch the video and learn more:
- Learn about Scorpius’ president and COO, Joe Payne, as a thought leader who is also approachable, energetic, and in-tune with client needs.
- Learn about Scorpius’ competitive advantages in biomanufacturing of small-volume, early-stage large molecules.
- Learn what it takes to produce an end product that can be shared with both prospective clients and prospective employees.
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Bettina Brierley, chief commercial officer at Celtic Renewables, discusses commercialization of biosolvents for pharmaceutical manufacturing.
From AI validation to microstructure imaging, AAPS PharmSci 360 speakers pushed toward faster drug development backed by stronger evidence. Here are PharmTech's biggest takeaways.
The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.
Trending on Pharmaceutical Technology
1
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
2
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
3
The Impact of Excipients on Continuous Manufacturing and the Risk of Nitrites
4
Our Biggest Takeaways From AAPS PharmSci 360
5